Echo Therapeutics Begins Testing of NextGen CGM System Components

Thursday, June 30, 2016

Echo Therapeutics, Inc., a medical device company focused on non-invasive continuous glucose monitoring (CGM) and associated technologies, today announced that it began stand-alone and integrated testing of its NextGen continuous glucose monitoring system (CGM) prototype components and formally selected a Clinical Research Organization (CRO) for its regulatory and clinical strategy. Rigorous testing of each component independently and as an integrated system will continue as the Company optimizes its system in preparation for future clinical and regulatory trials. Echo began hardware and software testing of the NextGen Exfoliator and the Bluetooth transmitter. As previously announced, the Company continues to test the NextGen sensor element and hydrogel. Verification testing of the new Application Programming Interface (API) and software application (App) is complete.

Echo’s NextGen CGM system is more consumer-friendly and substantially less expensive than the prior version. The new streamlined design includes a self-use exfoliator, a new exfoliator tip, a more sensitive sensor element with increased consistency, and a reusable transmitter and battery. Transmitted glucose information is displayed on a new CGM App using Echo’s API technology.

“I am excited about the progress our Development Team has made in the development and testing of the NextGen components and on integrating them into a system. We received very positive feedback from our demonstration of the NextGen self-exfoliator and App at the 2016 American Diabetes Association Scientific Sessions in New Orleans this month.” said Scott W. Hollander, Echo’s President and CEO. “We look forward to collaborating with our experienced CRO on the clinical development and regulatory pathway of our technology.”